Richard A. Paulson - 28 Feb 2022 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role: President and CEO, Director
Signature: /s/ Nancy Smith as Attorney-in-Fact for Richard Paulson
Issuer symbol: KPTI
Transactions as of: 28 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 02 Mar 2022, 14:14:16 UTC
Next filing: 05 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KPTI	Common Stock	Award	$0	+288,750	+77%	$0.000000	661,950	28 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KPTI	Stock Option (right to buy)	Award	$0	+360,000		$0.000000	360,000	28 Feb 2022	Common Stock	360,000	$10.33	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.
F2	This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.